Ocular biomarkers for early detection of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 22, Issue 1, 2010, Pages 1-16

  Frost, Shaun ^a,b   Martins, Ralph N ^a,c,d   Kanagasingam, Yogesan ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b CSIRO   (Australia)

^c HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

Author keywords

Aging; amyloid protein; cataract; diagnosis; lens; retinal; vision disorders

Indexed keywords

BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; DIMEBON; LATREPIRIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; EARLY DIAGNOSIS; EYE DISEASE; HUMAN; LENS; MEDICAL LITERATURE; MORPHOLOGY; OPTIC DISK; PRIORITY JOURNAL; PUPIL REFLEX; RETINA; REVIEW; SCREENING TEST; VITREOUS BODY;

EID: 78650673534     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100819     Document Type: Review

References (160)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191.
2. Brookmeyer R, Gray S, Kawas C (1998) Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 88, 1337-1342.
3. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cum-mings JL, DeKosky ST (2001) Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56, 1133-1142.
4. Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (2004) The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology 62, 1984-1989.
5. Bates KA, Sohrabi HR, Rodrigues M, Beilby J, Dhaliwal SS, Taddei K, Criddle A, Wraith M, Howard M, Martins G, Paton A, Mehta P, Foster JK, Martins IJ, Lautenschlager NT, Mastaglia FL, Laws SM, Gandy SE, Martins RN (2009) Association of cardiovascular factors and Alzheimer's disease plasma amyloid-beta protein in subjective memory com-plainers. J Alzheimers Dis 17, 305-318.
6. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shep-ardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14, 837-842.
7. Xu F, Davis J, Miao J, Previti ML, Romanov G, Ziegler K, Van Nostrand WE (2005) Protease nexin-2/amyloid beta-protein precursor limits cerebral thrombosis. Proc Natl Acad Sci USA 102, 18135-18140.
8. Turner PR, O'Connor K, Tate WP, Abraham WC (2003) Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog Neurobiol 70, 1-32.
9. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325, 733-736.
10. Suo Z, Humphrey J, Kundtz A, Sethi F, Placzek A, Crawford F, Mullan M (1998) Soluble Alzheimers beta-amyloid constricts the cerebral vasculature in vivo. Neurosci Lett 257, 77-80.
11. Chan C-W, Dharmarajan A, Atwood CS, Huang X, Tanzi RE, Bush AI, Martins RN (1999) Anti-apoptotic action of Alzheimer Abeta. Alzheimers Rep 2, 113-119.
12. Hardy J, Cullen K (2006) Amyloid at the blood vessel wall. Nat Med 12, 756-757.
13. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD (2010) The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoSOne 5, e9505.
14. Butterfield DA, Lauderback CM (2002) Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 32, 1050-1060.
15. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862.
16. Tanzi RE, Bertram L (2001) New frontiers in Alzheimer's disease genetics. Neuron 32, 181-184.
17. Yin YI, Bassit B, Zhu L, Yang X, Wang C, Li YM (2007) {gamma}-Secretase Substrate Concentration Modulates the Abeta42/Abeta40 Ratio: Implications for Alzheimer disease. J Biol Chem 282, 23639-23644.
18. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, SantaCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M, Ashe KH (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25, 10637-10647.
19. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, In-gelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan C, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskows-ki M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309, 476-481.
20. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe KH, Hyman BT (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 168, 1598-1607.
21. Bush AI (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23, 1031-1038.
22. Bush AI (2003) The metallobiology of Alzheimer's disease. Trends Neurosci 26, 207-214.
23. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177.
24. Parker MH, Chen R, Conway KA, Lee DH, Luo C, Boyd RE, Nortey SO, Ross TM, Scott MK, Reitz AB (2002) Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R- (dipropylamino)-1,2,3,4-tetrahydronaphthale ne: an inhibitor of beta-amyloid(1-42) aggregation. Bioorg Med Chem 10, 35653569.
25. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372, 207-215.
26. Medivation, Press release 3 March Pfizer and Mediva-tion announce results from two Phase 3 studies in Dimebon (latrepirdine*) Medivation website online, http://investors. medivation.com/releasedetail.cfm?ReleaseID=448818, Accessed June 2010.
27. Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120, 701-713.
28. Wilson RS, Mendes De Leon CF, Barnes LL, Schneider JA, Bienias JL, Evans DA, Bennett DA (2002) Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 287, 742-748.
29. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM (2005) Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 48, 913-922.
30. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, Sheline YI, Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 25, 7709-7717.
31. Schaffer C, Donlon P (1983) Medical causes of psychiatric symptoms in the eldery. Clin Gerontol 1, 3-18.
32. Thal LJ, Kantarci K, Reiman EM, Klunk WE, Weiner MW, Zetterberg H, Galasko D, Pratico D, Griffin S, Schenk D, Siemers E (2006) The role ofbiomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord 20, 6-15.
33. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103.
34. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59, 512-519.
35. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL (2007) Imaging beta-amyloid burden in aging and dementia. Neurology 68, 1718-1725.
36. Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA (2009) Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease. Arch Neurol 66, 1469-1475.
37. Selkoe DJ (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81, 741-766.
38. Bu G (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333-344.
39. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
40. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schur-mann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PI-CALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
41. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tav-ernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccar-di P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licas-tro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzou-rio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
42. Bertram L, Tanzi RE (2008) Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 9, 768-778.
43. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S, Ackermann U, Cowie TF, Currie J, Chan SG, Jones G, Tochon-Danguy H, O'Keefe G, Masters CL, Rowe CC (2008) Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 46, 1688-1697.
44. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P, Mathis CA, Klunk WE, Masters CL, Rowe CC (2007) Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844.
45. Simonsen AH, McGuire J, Podust VN, Davies H, Minthon L, Skoog I, Andreasen N, Wallin A, Waldemar G, Blennow K (2008) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging 29, 961-968. (Pubitemid 351697984)
46. Katz B, Rimmer S (1989) Ophthalmologic manifestations of Alzheimer's disease. Surv Ophthalmol 34, 31-43.
47. Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ (1987) Assessment of visual impairment in patients with Alzheimer's disease. Am J Ophthalmol 104, 113-120.
48. Trick GL, Trick LR, Morris P, Wolf M (1995) Visual field loss in senile dementia of the Alzheimer's type. Neurology 45, 68-74.
49. Whittaker KW, Burdon MA, Shah P (2002) Visual field loss and Alzheimer's disease. Eye (Lond) 16, 206-208.
50. Pache M, Smeets CH, Gasio PF, Savaskan E, Flammer J, Wirz-Justice A, Kaiser HJ (2003) Colour vision deficiencies in Alzheimer's disease. Age Ageing 32, 422-426.
51. Cogan DG (1987) Alzheimer syndromes. Am J Ophthalmol 104, 183-184.
52. Cronin-Golomb A, Sugiura R, Corkin S, Growdon JH (1993) Incomplete achromatopsia in alzheimer's disease. Neurobiol Aging 14, 471-477.
53. Lakshminarayanan V, Lagrave J, Kean ML, Dick M, Shankle R (1996) Vision in dementia: contrast effects. Neurol Res 18, 9-15.
54. Crow RW, Levin LB, LaBree L, Rubin R, Feldon SE (2003) Sweep visual evoked potential evaluation of contrast sensitivity in Alzheimer's dementia. Invest Ophthalmol Vis Sci 44, 875-878.
55. Nissen MJ, Corkin S, Buonanno FS, Growdon JH, Wray SH, Bauer J (1985) Spatial vision in Alzheimer's disease. General findings and a case report. Arch Neurol 42, 667-671.
56. Mendola JD, Cronin-Golomb A, Corkin S, Growdon JH (1995) Prevalence of visual deficits in Alzheimer's disease. Optom Vis Sci 72, 155-167.
57. Schlotterer G, Moscovitch M, Crapper-McLachlan D (1984) Visual processing deficits as assessed by spatial frequency contrast sensitivity and backward masking in normal ageing and Alzheimer's disease. Brain 107 (Pt 1), 309-325.
58. Mielke R, Kessler J, Fink G, Herholz K, Heiss WD (1995) Dysfunction of visual cortex contributes to disturbed processing of visual information in Alzheimer's disease. Int J Neurosci 82, 1-9.
59. Morrison JH, Hof PR, Bouras C (1991) An anatomic substrate for visual disconnection in Alzheimer's disease. Ann N Y Acad Sci 640, 36-43.
60. Gilmore GC, Wenk HE, Naylor LA, Koss E (1994) Motion Perception and Alzheimer's Disease. J Gerontol 49, P52-P57.
61. Sadun AA, Bassi CJ (1990) Optic nerve damage in Alzheimer's disease. Ophthalmology 97, 9-17.
62. Fletcher WA, Sharpe JA (1988) Smooth pursuit dysfunction in Alzheimer's disease. Neurology 38, 272-277.
63. Mendez MF, Tomsak RL, Remler B (1990) Disorders ofthe visual system in Alzheimer's disease. J Clin Neuroophthal-mol 10, 62-69.
64. Leuba G (1995) Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer's disease. Neu-ropathol Appl Neurobiol 21, 410.
65. McKee AC, Au R, Cabral HJ, Kowall NW, Seshadri S, Ku-bilus CA, Drake J, Wolf PA (2006) Visual association pathology in preclinical Alzheimer disease. J Neuropathol Exp Neurol 65, 621-630.
66. Bentley P, Driver J, Dolan RJ (2008) Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. Brain 131, 409-424.
67. Herholz K, Weisenbach S, Zundorf G, Lenz O, Schroder H, Bauer B, Kalbe E, Heiss WD (2004) In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 21, 136143.
68. Nobili L, Sannita WG (1997) Cholinergic modulation, visual function and Alzheimer's dementia. Vision Res 37, 35593571.
69. Scinto LF, Daffner KR, Dressler D, Ransil BI, Rentz D, Wein-traub S, Mesulam M, Potter H (1994) Apotential noninvasive neurobiological test for Alzheimer's disease. Science 266, 1051-1054.
70. Idiaquez J, Alvarez G, Villagra R, San Martin RA (1994) Cholinergic supersensitivity of the iris in Alzheimer's disease. J Neurol Neurosurg Psychiatry 57, 1544-1545.
71. Pomara N, Sitaram N (1995) Detecting Alzheimer's disease. Science 267, 1579-1580; author reply 1580-1571.
72. Iijima A, Haida M, Ishikawa N, Ueno A, Minamitani H, Shi-nohara Y (2003) Re-evaluation of tropicamide in the pupillary response test for Alzheimer's disease. Neurobiol Aging 24, 789-796.
73. Gomez-Tortosa E, del Barrio A, Jimenez-Alfaro I (1996) Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. Acta Neurol Scand 94, 104-109.
74. Grunberger J, Linzmayer L, Walter H, Rainer M, Masching A, Pezawas L, Saletu-Zyhlarz G, Stohr H, Grunberger M (1999) Receptor test (pupillary dilatation after application of 0.01% tropicamide solution) and determination of central nervous activation (Fourier analysis ofpupillary oscillations) in patients with Alzheimer's disease. Neuropsychobiology 40, 40-46.
75. Kalman J, Kanka A, Magloczky E, Szoke A, Jardanhazy T, Janka Z (1997) Increased mydriatic response to tropicamide is a sign of cholinergic hypersensitivity but not specific to late-onset sporadic type of Alzheimer's dementia. Biol Psychiatry 41,909-911.
76. Robles A, Tourino R, Sesar A, Suarez P, Noya M (1996) Experience with pupil tropicamide test in Alzheimer's disease. Rev Neurol 24, 65-68.
77. Kono K, Miyao M, Ishihara S, Takagi A, Ikari H, Suzuki Y, Iguchi A (1996) Hypersensitivity in the pupil dilation response to a cholinergic antagonist in patients with Alzheimer's disease and Down's syndrome. Nippon Ronen Igakkai Zasshi 33, 829-834.
78. Arai H, Terajima M, Nakagawa T, Higuchi S, Mochizuki H, Sasaki H (1996) Pupil dilatation assay by tropicamide is modulated by apolipoprotein E epsilon 4 allele dosage in Alzheimer's disease. Neuroreport 7, 918-920.
79. Tohgi H, Abe T, Hashiguchi K, Saheki M, Takahashi S (1994) Remarkable reduction in acetylcholine concentration in the cerebrospinal fluid from patients with Alzheimer type dementia. Neurosci Lett 177, 139-142.
80. Hou RH, Samuels ER, Raisi M, Langley RW, Szabadi E, Bradshaw CM (2006) Why patients with Alzheimer's disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus. Psychopharmacology (Berl) 184, 95-106.
81. FitzSimon JS, Waring SC, Kokmen E, McLaren JW, Brubak-er RF (1997) Response of the pupil to tropicamide is not a reliable test for Alzheimer disease. Arch Neurol 54, 155-159.
82. Kardon RH (1998) Drop the Alzheimer's drop test. Neurology 50, 588-591.
83. Caputo L, Casartelli M, Perrone C, Santori M, Annoni G, Vergani C (1998) The 'eye test' in recognition of late-onset Alzheimer's disease. Arch Gerontol Geriatr 27, 171-177.
84. Fridh M, Havelius U, Elofsson G, Hindfelt B (1996) The pupillary response to tropicamide in Alzheimer's disease. Acta Ophthalmol Scand74, 276-279.
85. Growdon JH, Graefe K, Tennis M, Hayden D, Schoenfeld D, Wray SH (1997) Pupil dilation to tropicamide is not specific for Alzheimer disease. Arch Neurol 54, 841-844.
86. Kurz A, Marquard R, Fremke S, Leipert KP (1997) Pupil dilation response to tropicamide: a biological test for Alzheimer's disease? Pharmacopsychiatry 30, 12-15.
87. Marx JL, Kumar SR, Thach AB, Kiat-Winarko T, Fram-bach DA (1995) Detecting Alzheimer's disease. Science 267, 1577; author reply 1580-1571.
88. Reitner A, Baumgartner I, Thuile C, Baradaran Dilmaghani R, Ergun E, Kaminski S, Lukas J, Dal Bianco P (1997) The mydriatic effect oftropicamide and its diagnostic use in Alzheimer's disease. Vision Res 37, 165-168.
89. Loupe DN, Newman NJ, Green RC, Lynn MJ, KK WI, Geis TC, Edelhauser HF (1996) Pupillary response to tropicamide in patients with Alzheimer disease. Ophthalmology 103, 495503.
90. Treloar AJ, Assin M, Macdonald AJ (1996) Pupillary response to topical tropicamide as a marker for Alzheimer's disease. Br J Clin Pharmacol 41, 256-257.
91. Granholm E, Morris S, Galasko D, Shults C, Rogers E, Vukov B (2003) Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease. Int J Psychophysiol 47, 95-115.
92. Higuchi S, Matsushita S, Hasegawa Y, Muramatsu T, Arai H, Hayashida M (1997) Apolipoprotein E epsilon 4 allele and pupillary response to tropicamide. Am J Psychiatry 154, 694-696.
93. Sacks B, Smith S (1989) People with Down's syndrome can be distinguished on the basis of cholinergic dysfunction. J Neurol Neurosurg Psychiatry 52, 1294-1295.
94. Higuchi S, Matsushita S, Hasegawa Y, Muramatsu T, Arai H (1997) Pupillary response to tropicamide in Japanese patients with alcoholic dementia, Alzheimer's disease, and vascular dementia. Exp Neurol 144, 199-201.
95. Den Heijer JC, Bollen WL, Reulen JP, van Dijk JG, Kramer CG, Roos RA, Buruma OJ (1988) Autonomic nervous function in Huntington's disease. Arch Neurol 45, 309-312.
96. Meyer S, Gibb T, Jurkovich GJ (1993) Evaluation and significance of the pupillary light reflex in trauma patients. Ann EmergMed 22, 1052-1057.
97. Steinhauer SR, Hakerem G (1992) The pupillary response in cognitive psychophysiology and schizophrenia. Ann N Y Acad Sci 658, 182-204.
98. Van Diemen HA, Van Dongen MM, Nauta JJ, Lanting P, Pol-man CH (1992) Pupillary light reflex latency in patients with multiple sclerosis. Electroencephalogr Clin Neurophysiol 82, 213-219.
99. Loewenfeld IE (1999) The pupil: Anatomy, physiology, and clinical applications.
100. Fotiou DF, Brozou CG, Haidich AB, Tsiptsios D, Nakou M, Kabitsi A, Giantselidis C, Fotiou F (2007) Pupil reaction to light in Alzheimer's disease: evaluation ofpupil size changes and mobility. Aging Clin Exp Res 19, 364-371.
101. Fotiou F, Fountoulakis KN, Tsolaki M, Goulas A, Palikaras A (2000) Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report. Int J Psychophysiol 37, 111-120.
102. Prettyman R, Bitsios P, Szabadi E (1997) Altered pupillary size and darkness and light reflexes in Alzheimer's disease. J Neurol Neurosurg Psychiatry 62, 665-668.
103. Fotiou DF, Brozou CG, Tsiptsios DJ, Fotiou A, Kabitsi A, Nakou M, Giantselidis C, Goula A (2007) Effect of age on pupillary light reflex: evaluation ofpupil mobility for clinical practice and research. Electromyogr Clin Neurophysiol 47, 11-22.
104. Hanson SR, Hasan A, Smith DL, Smith JB (2000) The major in vivo modifications of the human water-insoluble lens crystallins are disulfide bonds, deamidation, methionine oxidation and backbone cleavage. Exp Eye Res 71, 195-207.
105. Spector A (1995) Oxidative stress-induced cataract: mechanism of action. FASEBJ 9, 1173-1182.
106. Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT, Jr., Bush AI (2003) Cy-tosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 361, 1258-1265.
107. Yoneda S, Hara H, Hirata A, Fukushima M, Inomata Y, Tani-hara H (2005) Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol 49, 106-108.
108. Moncaster JA, Pineda R, Moir RD, Lu S, Burton MA, Ghosh JG, Ericsson M, Soscia SJ, Mocofanescu A, Folkerth RD, Robb RM, Kuszak JR, Clark JI, Tanzi RE, Hunter DG, Goldstein LE (2010) Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One 5, e10659.
109. Frederikse PH, Garland D, Zigler JS, Jr., Piatigorsky J (1996) Oxidative stress increases production of beta-amyloid precursor protein and beta-amyloid βAbeta) in mammalian lenses, and Abeta has toxic effects on lens epithelial cells. J Biol Chem 271, 10169-10174.
110. Goldstein LE, Moir R, Lu S, Fu L, Chadwick O, Arnett E, Ericsson M, Klunk W, Mathis C, Chylack LT, Jr., Clark J, Tanzi R, Moncaster JA (2006) Non-invasive early detection of beta-amyloid molecular pathology by quasi-elastic light scattering in vivo. Alzheimers Dement 2, S133.
111. Ansari RR, Datiles MB, 3rd (1999) Use of dynamic light scattering and Scheimpflug imaging for the early detection of cataracts. Diabetes Technol Ther 1, 159-168.
112. Datiles MB, 3rd, Ansari RR, Reed GF (2002) A clinical study ofthe human lens with a dynamic light scattering device. Exp Eye Res 74, 93-102.
113. Datiles MB, 3rd, Ansari RR, Suh KI, Vitale S, Reed GF, Zigler JS, Jr., Ferris FL, 3rd (2008) Clinical detection ofpre-cataractous lens protein changes using dynamic light scattering. Arch Ophthalmol 126, 1687-1693.
114. Sudworth CD (2006) Advances in Raman spectroscopy for the diagnosis of Alzheimer's disease. Proc SPIE 6093, 139146.
115. Hanlon EB, Perelman LT, Vitkin EI, Greco FA, McKee AC, Kowall NW (2008) Scattering differentiates Alzheimer disease in vitro. Opt Lett 33, 624-626.
116. Hanlon EB, Itzkan I, Dasari RR, Feld MS, Ferrante RJ, McKee AC, Lathi D, Kowall NW (1999) Near-infrared fluorescence spectroscopy detects Alzheimer's disease in vitro. Photochem Photobiol 70, 236-242.
117. Archer JKJ, Sudworth CD, Williams R, How T, Stone N, Mann D, Black RA (2007) Improvements in Alzheimer' Disease Diagnosis using Principal Component Analysis (PCA) in Combination with Raman Spectroscopy. Proc SPIE 6628, 37.
118. Zipfel WR, Williams RM, Christie R, Nikitin AY, Hyman BT, Webb WW (2003) Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci U S A 100, 70757080.
119. Paquet C, Boissonnot M, Roger F, Dighiero P, Gil R, Hugon J (2007) Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 420, 97-99.
120. Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL (2007) Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci 48, 2285-2289.
121. Hedges TR, 3rd, Perez Galves R, Speigelman D, Barbas NR, Peli E, Yardley CJ (1996) Retinal nerve fiber layer abnormalities in Alzheimer's disease. Acta Ophthalmol Scand 74, 271-275.
122. Tsai CS (1991) Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch Ophthalmol 109, 199.
123. Danesh-Meyer HV, Birch H, Ku JY, Carroll S, Gamble G (2006) Reduction of optic nerve fibers in patients with Alzheimer disease identified by laser imaging. Neurology 67, 1852-1854.
124. Bayer AU, Ferrari F, Erb C (2002) High Occurrence Rate ofGlaucoma among Patients with Alzheimer's Disease. Eur Neurol 47, 165-168.
125. Bayer AU, Keller ON, Ferrari F, Maag KP (2002) Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol 133, 135-137.
126. Bayer AU, Ferrari F (2002) Severe progression of glaucoma-tous optic neuropathy in patients with Alzheimer's disease. Eye 16, 209-212.
127. Nesher R, Trick GL (1991) The pattern electroretinogram in retinal and optic nerve disease. A quantitative comparison of the pattern of visual dysfunction. Doc Ophthalmol 77, 225-235.
128. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, Ransom NL, Tahzib NG, Re-itsamer HA, Levkovitch-Verbin H, Quigley HA, Zack DJ (2002) Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 43, 1077-1087.
129. Yin H, Chen L, Chen X, Liu X (2008) Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. Med Hypotheses 71, 77-80.
130. Guo L, Salt TE, Luong V, Wood N, Cheung W, Maass A, Ferrari G, Russo-Marie F, Sillito AM, Cheetham ME, Moss SE, Fitzke FW, Cordeiro MF (2007) Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U SA 104, 1344413449.
131. Sun C, Sun (2009) Retinal vascular caliber: systemic, environmental, and genetic associations. Surv Ophthalmol 54, 74.
132. Loffler KU (1995) Immunoreactivity against tau, amyloid precursor protein, and beta-amyloid in the human retina. Invest Ophthalmol Vis Sci 36, 24.
133. Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z (2009) Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. Am J Pathol 175,2099-2110.
134. Perez SE, Lumayag S, Kovacs B, Mufson EJ, Xu S (2009) Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease. Invest Ophthalmol Vis Sci 50, 793800.
135. Parisi V, Restuccia R, Fattapposta F, Mina C, Bucci MG, Pierelli F (2001) Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 112, 1860-1867.
136. Iseri PK, Altinas O, Tokay T, Yuksel N (2006) Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neu-roophthalmol 26, 18-24.
137. Katz B, Rimmer S, Iragui V, Katzman R (1989) Abnormal pattern electroretinogram in Alzheimer's disease: evidence for retinal ganglion cell degeneration? Ann Neurol 26, 221-225.
138. Trick GL, Barris MC, Bickler-Bluth M (1989) Abnormal pattern electroretinograms in patients with senile dementia of the Alzheimer type. Ann Neurol 26, 226-231.
139. Blanks JC, Hinton DR, Sadun AA, Miller CA (1989) Retinal ganglion cell degeneration in Alzheimer's disease. Brain Res 501, 364-372.
140. Blanks JC, Schmidt SY, Torigoe Y, Porrello KV, Hinton DR, Blanks RH (1996) Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging 17, 385-395.
141. Blanks JC, Torigoe Y, Hinton DR, Blanks RH (1996) Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging 17, 377-384.
142. Hinton DR, Sadun AA, Blanks JC, Miller CA (1986) Optic-nerve degeneration in Alzheimer's disease. N Engl J Med 315, 485-487.
143. Sadun AA, Bassi CJ (1990) The visual system in Alzheimer's disease. Res Publ Assoc Res NervMent Dis 67, 331-347.
144. Curcio CA, Drucker DN (1993) Retinal ganglion cells in Alzheimer's disease and aging. Ann Neurol 33, 248-257.
145. Davies DC, McCoubrie P, McDonald B, Jobst KA (1995) Myelinated axon number in the optic nerve is unaffected by Alzheimer's disease. Br J Ophthalmol 79, 596-600.
146. Ravona-Springer R, Davidson M, Noy S (2003) The role of cardiovascular risk factors in Alzheimer's disease. CNS Spe-ctr 8, 824-833.
147. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD (2003) Vascular pathology in Alzheimer disease: correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 62, 12871301.
148. Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B (2005) Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvas-culatures. JAnat 206, 319-348.
149. Zamir M, Brown N (1982) Arterial branching in various parts of the cardiovascular system. Am JAnat 163, 295-307.
150. Zamir M, Medeiros JA (1982) Arterial branching in man and monkey. J Gen Physiol 79, 353-360.
151. Chapman N, Dell'omo G, Sartini MS, Witt N, Hughes A, Thom S, Pedrinelli R (2002) Peripheral vascular disease is associated with abnormal arteriolar diameter relationships at bifurcations in the human retina. Clin Sci (Lond) 103, 111116.
152. Stanton AV, Wasan B, Cerutti A, Ford S, Marsh R, Sever PP, Thom SA, Hughes AD (1995) Vascular network changes in the retina with age and hypertension. J Hypertens 13, 17241728.
153. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Parara-jasegaram R, Pokharel GP, Mariotti SP (2004) Global data on visual impairment in the year Bull World Health Organ 82, 844-851.
154. Tamura H, Kawakami H, Kanamoto T, Kato T, Yokoyama T, Sasaki K, Izumi Y, Matsumoto M, Mishima HK (2006) High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci 246, 79-83.
155. Estermann S, Daepp GC, Cattapan-Ludewig K, Berkhoff M, Frueh BE, Goldblum D (2006) Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients. J Ocul Pharmacol Ther 22, 62-67.
156. Johnson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH (2002) The Alzheimer's A beta-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 99, 11830-11835.
157. Luibl V, Isas JM, Kayed R, Glabe CG, Langen R, Chen J (2006) Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 116, 378-385.
158. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johnson LV (2004) Characterization of beta. amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78, 243-256.
159. Dentchev T, Milam AH, Lee VMY, Trojanowski JQ, Dunaief JL (2003) Amyloid-,0 is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas1 1 Edited by Hans E. Grossniklaus, MD. Am J Ophthalmol 136, 787.
160. Viestenz A, Langenbucher A, Mardin CY (2006) Para-papillary autofluorescence as indicator for glaucoma. Klin Monatsbl Augenheilkd 223, 315-320.